NantHealth (NH) versus Its Peers Head to Head Analysis
NantHealth (NASDAQ: NH) is one of 20 publicly-traded companies in the “Medical Software & Technology Services” industry, but how does it contrast to its competitors? We will compare NantHealth to similar businesses based on the strength of its analyst recommendations, dividends, profitability, earnings, valuation, institutional ownership and risk.
Volatility and Risk
NantHealth has a beta of -1.32, meaning that its stock price is 232% less volatile than the S&P 500. Comparatively, NantHealth’s competitors have a beta of 1.19, meaning that their average stock price is 19% more volatile than the S&P 500.
Earnings and Valuation
This table compares NantHealth and its competitors revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|NantHealth||$100.38 million||-$184.10 million||-1.84|
|NantHealth Competitors||$413.57 million||-$24.61 million||390.66|
NantHealth’s competitors have higher revenue and earnings than NantHealth. NantHealth is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares NantHealth and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
6.1% of NantHealth shares are owned by institutional investors. Comparatively, 66.2% of shares of all “Medical Software & Technology Services” companies are owned by institutional investors. 21.6% of shares of all “Medical Software & Technology Services” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a summary of recent ratings and price targets for NantHealth and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
NantHealth currently has a consensus price target of $9.00, indicating a potential upside of 174.39%. As a group, “Medical Software & Technology Services” companies have a potential upside of 20.83%. Given NantHealth’s stronger consensus rating and higher probable upside, analysts plainly believe NantHealth is more favorable than its competitors.
NantHealth competitors beat NantHealth on 9 of the 12 factors compared.
NantHealth Company Profile
NantHealth, Inc. is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples. The Company also offers Nant Operating System (NantOS) and NantOS applications to healthcare providers and payors, self-insured employers and biopharmaceutical companies. It offers CLINICS, an integrated solution that includes GPS Cancer, NantOS and the NantOS applications. The CLINICS solution includes System Infrastructure, Knowledge Platform, Provider Platform and Payor Platform.
Receive News & Stock Ratings for NantHealth Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc. and related stocks with our FREE daily email newsletter.